- HK$7.41bn
- HK$9.91bn
- HK$4.17bn
Brief: Ssy Group Says NMPA Approved Passing Furosemide Injection
Brief: SSY Group Says Vonoprazan Fumarate Got Approval For Registration From NMPA China
Brief: SSY Group Obtained Approval For Drug Production And Registration For Deferasirox From NMPA China
Brief: SSY Group Obtains Approval For Drug Production & Registration For An Injection From NMPA
Brief: Ssy Group Says NMPA Approved Passing Of Consistency Evaluation Of Quality & Efficacy Of Generic Drugs For Glycerol Fructose And Sodium Chloride Injection
Brief: SSY Group Gets Approval For Drug Production, Registration For Injection From NMPA China
Brief: Ssy Group Obtained Approval From NMPA
Brief: SSY Group Posts 9M Unaudited Turnover Of HK$4,534 Mln
Brief: SSY Group Posts 9M Net Income HKD 919 Mln
Brief: SSY Group Says Cisatracurium Besilate Obtained Approval For Registration From NMPA
Brief: SSY Group Says NMPA Approved Passing Of Consistency Evaluation
Brief: SSY Group Appoints Qu Wanrong As An Executive Director
Brief: SSY Group Declares Interim Dividend Of HK$0.08 Per Share
Brief: Ssy Group Obtained Notice Of Approval For Drug Clinical Trial From NMPA
Brief: SSY Group Updates On Tender Regarding Procurement Of Bromhexine Hydrochloride Injection
Brief: SSY Group Says Trading Halt
Brief: HKEX Says Trading In Shares Of SSY Will Be Halted On Aug 14
Brief: SSY Group Obtained Approvals From NMPA
Brief: SSY Group Got Approvals For Drug Production And Registration From NMPA China